The current stock price of RWLK is 1.0501 USD. In the past month the price increased by 40.9%. In the past year, price increased by 24.35%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.83 | 224.14B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.61 | 203.30B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.43 | 150.59B | ||
| SYK | STRYKER CORP | 28.18 | 141.95B | ||
| IDXX | IDEXX LABORATORIES INC | 59.7 | 60.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.72 | 50.29B | ||
| RMD | RESMED INC | 25.84 | 37.34B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.43 | 36.44B | ||
| DXCM | DEXCOM INC | 34.12 | 24.75B | ||
| PODD | INSULET CORP | 71.6 | 23.02B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12.05 | 19.33B |
ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The firm offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.
REWALK ROBOTICS LTD
3 Hatnufa st. 6th fl., P.O. Box 161
Yokneam 2069203 IL
CEO: Larry Jasinski
Employees: 56
Phone: 97249590123
ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The firm offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.
The current stock price of RWLK is 1.0501 USD. The price increased by 6.07% in the last trading session.
RWLK does not pay a dividend.
RWLK has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
RWLK stock is listed on the Nasdaq exchange.
REWALK ROBOTICS LTD (RWLK) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
REWALK ROBOTICS LTD (RWLK) will report earnings on 2024-02-22, after the market close.
ChartMill assigns a technical rating of 9 / 10 to RWLK. When comparing the yearly performance of all stocks, RWLK is one of the better performing stocks in the market, outperforming 87.06% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to RWLK. RWLK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months RWLK reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -27.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.49% | ||
| ROE | -42.1% | ||
| Debt/Equity | 0 |
7 analysts have analysed RWLK and the average price target is 3.06 USD. This implies a price increase of 191.4% is expected in the next year compared to the current price of 1.0501.
For the next year, analysts expect an EPS growth of -21.12% and a revenue growth 162.79% for RWLK